July 2022 Vol 13, No 7

Catching & Addressing Threats to Care & Health, or CATCH, is a reporting system that tracks navigators’ interventions and their positive outcomes. Made a CATCH recently? Be recognized for your accomplishments!
With a malignancy like lung cancer, early detection can quite literally mean the difference between life and death. Despite this, lung cancer screening and incidental pulmonary nodule (IPN) management are still sorely lacking in the United States, according to Kim Parham, BSN, RN, CB-BN, vice president, Strategic Partnerships and Clinical Liaison, Thynk Health, and Shawn Perkins, BSN, RN, OCN, a thoracic services nurse navigator at Cone Health Cancer Center at Alamance Regional.
The CATCH for July 2022 is awarded to Shana Smith, MSN, RN, OCN. Ms Smith is the oncology nurse navigator for the malignant hematology patient population at Vidant Medical Center.
Navigation is still fairly new to the world of urology private practice, but thanks to the efforts of a few navigators who set out to identify and recover genitourinary (GU) oncology patients in need of care or lost to follow-up, navigators have solidified their place as part of the multidisciplinary team at Urology Austin, the largest urology group in Central Texas.
International patients seeking cancer treatment in the United States face a number of unique barriers to care, according to Elizabeth Paucar Harris, MBA, chief executive officer at H.O.P.E., Helping Our People Everywhere.
FDA-approved oral cancer drugs are not cheap, and many patients are unable to afford these promising therapies with extremely high price tags. Depending on the type of cancer and the drug used to treat it, the price of oral cancer therapy can range from about $10,000 to $25,000 per month.
It is well-known that one of the most common barriers to care faced by patients—and one of the most often dealt with by navigators—is transportation. When patients do not have reliable transportation, they cannot receive care for their cancer. This has a clear and significant impact on patient outcomes.
If drugmakers can’t turn a profit owing to his tax and regulatory policies, who’ll develop new treatments?

Results 1 - 9 of 9

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Country